have demonstrated amply the therapeutic efficacy of streptomycin in experimental bubonic and pneumonic plague. Since streptomycin appears to be unique among the antibiotics in that high levels of resistance may occur in bacteria at a single mutational step (Bryson and Demerec, 1950) , the occurrence of strains of Pasteurella pestis so resistant to this antibiotic as to be refractory to therapy would represent a major problem in the treatment of plague, especially in endemic areas. Consequently, a study of the factors underlying the efficacy of streptomycin therapy in plague as well as the probability of the occurrence of streptomycin resistance during the course of such therapy was undertaken.
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MATERIALS
One virulent strain (139-L) and two avirulent strains (A-1122 smooth, and A-1122NS nonsmooth) of Pa8teurella pestis were used in this study. Liquid cultures were grown in tryptose broth (Difco), and platings were made on the surface of tryptose agar plates since pour plates were found to be unsatisfactory. One unit of streptomycin sulfate (Pfizer) was equivalent to one microgram of streptomycin base.
Mice, Namru strain, (Garber and Hauth, 1950) and guinea pigs were used in virulence studies. P. pestis, strain 139-L, is highly virulent (LDco = 3 to 9 cells) when inoculated subcutaneously into these hosts. (Newcombe and Hawirko, 1949 The therapeutic value of streptomycin in experimental plague was evaluated in terms of subeffective and effective treatment. Therapy was initiated 48 hours after a subcutaneous inoculation of approximately 1 X 10 viable cells of either a streptomycin sensitive or resistant strain into mice. In the subeffective treatment, 2,000 units of streptomycin were administered twice subcutaneously within 7 hours to 40 mice of which half had received the sensitive strain and half the resistant strain. A similar number of mice inoculated with each strain were held as a control. Although all mice given subeffective therapy died within 9 days after inoculation, a marked difference in survival up to 6 days was noted between the two groups. Whereas 100 per cent of the mice inoculated with the resistant strain had died, only 25 per cent of the mice inoculated with the sensitive strain had succumbed. In the effective therapy, 2,000 units were administered subcutaneously twice within 7 hours for 4 successive days to 20 mice of which half had been inoculated with the sensitive strain and half with the resistant strain. An equal number of mice inoculated with each strain were held as a control. Four of the 7 fully resistant colonies recovered from 5 X 109 viable cells of strain 139-L exposed to 25 units of streptomycin per ml of medium were avirulent. These avirulent colonies may have originated either from resistant, avirulent cells or from resistant cells that had lost their virulence as a consequence of the mutation to streptomycin resistance. Since avirulence in P. pestts does not lead to streptomycin resistance, 2 mutations would be required to yield a resistant, avirulent cell. This interpretation must consider the relatively low mutation rate, 10-12, for streptomycin resistance and the relatively high virulence (LDso = 3 to 9) of strain 139-L. It appears more likely that a mutation resulting in streptomycin resistance may lead also to avirulence. A mutation to streptomycin resistance in E. coli may result also in an alteration in other characters, such as growth rate, duration of lag period, and nutritional requirements (Demerec, 1950) .
Although resistant, virulent strains of P. pestU are refractory to streptomycin, the occurrence of such strains in the therapeutic treatment of plague is not considered a potential hazard due to a combination of 3 factors: high sensitivity to relatively low concentrations of streptomycin, a relatively low mutation rate from sensitivity to resistance, and the lack of absolute correlation between virulence and resistance in resistant mutants from virulent strains. Consequently, the few virulent, resistant cells that may occur after streptomycin therapy would probably not survive the defensive mechanism of the host.
